CHIP Verichip (MM)

VeriChip Corporation (the ๏ฟฝCompany๏ฟฝ) (NASDAQ: CHIP), a provider of radio frequency identification (RFID) systems for healthcare and patient-related needs, will be exhibiting at the American Academy of Forensic Sciences (AAFS) 60th Anniversary Scientific Meeting in Washington, D.C. from February 20-22. The conference, which will take place at the Marriott Wardman Park Hotel, is the premier event for forensic science professionals and the industry๏ฟฝs source for cutting-edge information. The Company will demonstrate its VeriTrace๏ฟฝ System to coroners, medical examiners and other forensics experts during the conference, which has generated a majority of VeriTrace sales historically. VeriTrace is designed to assist state and federal agencies in the management of emergency situations and disaster recovery using implantable RFID technology. The VeriTrace System includes an implantable RFID microchip, a VeriTrace Bluetooth๏ฟฝ handheld reader, a customized Ricoh 500SE Digital Camera capable of receiving both RFID scanned data and GPS data wirelessly, and a Web-enabled database for gathering and storing information and images captured during emergency response operations. This database ensures the precise collection, storage and inventory of all data and images related to remains and the associated evidentiary items. The Web-enabled database also allows the recreation of an accurate and complete reconstruction of a disaster setting, crime scene or similar setting where recreation is necessary. About VeriChip VeriChip Corporation, headquartered in Delray Beach, Florida, develops, markets and sells RFID systems used to identify, locate and protect people and assets. VeriChip's goal is to become the leading provider of RFID systems for people in the healthcare industry. The Company recently began marketing its VeriMed(TM) Patient Identification System, a passive RFID system for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip, the implantable VeriChip(TM), cleared for medical use in October 2004 by the United States Food and Drug Administration. For more information on VeriChip, please call 1-800-970-2447, or email info@verichipcorp.com. Additional information can be found online at http://www.verichipcorp.com. Statements about the Company's future expectations, including growth of the business and success of the Company๏ฟฝs marketing and sales initiative, and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and the Company's actual results could differ materially from expected results. Information about factors that could affect the Company๏ฟฝs business is set forth in the Company๏ฟฝs various filings with the Securities and Exchange Commission, including those set forth in the Company๏ฟฝs 10-K filed on April๏ฟฝ2, 2007, under the caption ๏ฟฝRisk Factors.๏ฟฝ The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.